NEW YORK (GenomeWeb) – Liquid biopsy technologies gained one of their first solid footholds in the clinical care of cancer patients this past year. At the same time, researchers turned their eyes to proving utility in other niches, and funders poured support behind companies who hope to translate these approaches to the early detection and even prevention of cancer.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.